EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders

Cristina Nanni; Christophe M Deroose; Sona Balogova; Constantin Lapa; Nadia Withofs; Manil Subesinghe; Bastien Jamet; Elena Zamagni; Davide Ippolito; Michel Delforge; Francoise Kraeber-Bodéré

doi:10.1007/s00259-024-06858-9

EANM guidelines on the use of [¹⁸F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders

Eur J Nucl Med Mol Imaging. 2024 Dec;52(1):171-192. doi: 10.1007/s00259-024-06858-9. Epub 2024 Aug 29.

Authors

Cristina Nanni¹, Christophe M Deroose^{2

3}, Sona Balogova^{4

5}, Constantin Lapa⁶, Nadia Withofs^{7

8}, Manil Subesinghe⁹, Bastien Jamet¹⁰, Elena Zamagni^{11

12}, Davide Ippolito^{13

14}, Michel Delforge¹⁵, Francoise Kraeber-Bodéré¹⁶

Affiliations

¹ Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
² Nuclear Medicine, University Hospitals (UZ) Leuven, 3000, Leuven, Belgium.
³ Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
⁴ Nuclear Medicine, Comenius University, Bratislava, Slovakia.
⁵ Médecine Nucléaire, Hôpital Tenon, GH AP.SU, Paris, France.
⁶ Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
⁷ Division of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, CHU of Liege, Liege, Belgium.
⁸ GIGA-CRC in Vivo Imaging, University of Liege, Liege, Belgium.
⁹ Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
¹⁰ Médecine Nucléaire, CHU Nantes, F-44000, Nantes, France.
¹¹ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. [email protected].
¹² Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy. [email protected].
¹³ Department of Diagnostic Radiology, Fondazione IRCCS San Gerardo dei Tintori, Via Pergolesi 33, 20900, Monza, Italy.
¹⁴ University of Milano-Bicocca, School of Medicine, Via Cadore 33, 20090, Monza, Italy.
¹⁵ University Hospitals (UZ) Leuven, 3000, Leuven, Belgium.
¹⁶ Nantes Université, Univ Angers, INSERM, CNRS, CRCI2NA, F-44000, Nantes, France.

Abstract

We provide updated guidance and standards for the indication, acquisition, and interpretation of [¹⁸F]FDG PET/CT for plasma cell disorders. Procedures and characteristics are reported and different scenarios for the clinical use of [¹⁸F]FDG PET/CT are discussed. This document provides clinicians and technicians with the best available evidence to support the implementation of [¹⁸F]FDG PET/CT imaging in routine practice and future research.

Keywords: EANM guidelines; Multiple myeloma; Plasma cell disorders; [18F]FDG PET/CT.

Publication types

Practice Guideline

MeSH terms

Fluorodeoxyglucose F18*
Humans
Neoplasm Staging
Nuclear Medicine / standards
Positron Emission Tomography Computed Tomography* / standards
Prognosis
Radiopharmaceuticals

Substances

Fluorodeoxyglucose F18
Radiopharmaceuticals